Papers/PMID:22019490
Melatonin as adjuvant cancer care with and without chemotherapy: a systematic review and meta-analysis of randomized trials.
Integrative cancer therapies2012The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
melatonin — decreases all-cause mortality
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×1“In trials combining MLT with chemotherapy, adjuvant MLT decreased 1-year mortality (RR = 0.60; 95% CI = 0.54-0.67) and improved outcomes of complete response, partial response, and stable disease; pooled RRs were 2.53 (1.36-4.71), 1.70 (1.37-2.12), and 1.15 (1.00-1.33), respectively.”
Quoted verbatim from Melatonin as adjuvant cancer care with and without chemotherapy: a systematic review and meta-analysis of randomized trials.. - Study
- meta-analysis
- Population
- solid tumor cancer patients; subgroup of trials combining melatonin with chemotherapy
Effect 0.6 risk ratio, 95% CI 0.54 to 0.67
Melatonin as adjuvant cancer care with and without chemotherapy: a systematic review and meta-analysis of randomized trials.2012PMID:22019490Permalink